Compare GSHD & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | NEO |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | Specialty Insurers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 891.2M | 1.0B |
| IPO Year | 2018 | 2008 |
| Metric | GSHD | NEO |
|---|---|---|
| Price | $39.59 | $8.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $72.50 | $13.38 |
| AVG Volume (30 Days) | 362.8K | ★ 2.0M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | N/A |
| Revenue This Year | $16.40 | $10.63 |
| Revenue Next Year | $18.53 | $9.73 |
| P/E Ratio | $39.67 | ★ N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $35.84 | $4.72 |
| 52 Week High | $113.00 | $13.74 |
| Indicator | GSHD | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 53.18 |
| Support Level | $39.99 | $8.68 |
| Resistance Level | $46.40 | $8.84 |
| Average True Range (ATR) | 2.32 | 0.41 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 49.41 | 39.14 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.